Author

Mathilde Bourdin

University of Geneva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Assay:electronic health records· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Bita Asghariastanehei· 1 shared Cyril Castelbou· 1 shared Élie NaderiD· 1 shared Franciele de LimaiD· 1 shared Gorane Rodríguez-Urquirizar· 1 shared Hélène GuizouarniD· 1 shared José M. Fernández‐FernándeziD· 1 shared Lars KaestneriD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Bita Asghariastanehei

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Otenabant is a Selective Antagonist of Human PIEZO1

Vincent Jaquet, Reeta Penttinen, Gorane Rodríguez-Urquirizar, Cyril Castelbou, Yves Cambet, Nicolas Rosa, Mathilde Bourdin, Bita Asghariastanehei, Franciele de Lima, Marie Martin, Élie Nader, Selma Angèlica Serra, José M. Fernández‐Fernández, Nicoletta Murciano, Philippe Connes, , Nicolas Demaurex

The paper identifies Otenabant, a CB1 antagonist, as a potent and selective PIEZO1 inhibitor through high-throughput screening and validates its effects across multiple assays.

bioRxiv · Apr 30, 2026 · PreprintPharmacology & Toxicology